enGene Holdings Inc. (NASDAQ:ENGN – Get Free Report) major shareholder Growth Opportunities F. Forbion bought 341,332 shares of the company’s stock in a transaction dated Monday, September 30th. The shares were purchased at an average price of $6.34 per share, with a total value of $2,164,044.88. Following the transaction, the insider now owns 2,400,791 shares of the company’s stock, valued at $15,221,014.94. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
enGene Trading Down 3.0 %
ENGN traded down $0.28 during midday trading on Friday, reaching $9.02. 110,205 shares of the company were exchanged, compared to its average volume of 113,105. The company has a debt-to-equity ratio of 0.09, a quick ratio of 19.52 and a current ratio of 19.52. enGene Holdings Inc. has a one year low of $4.42 and a one year high of $43.00. The stock has a market capitalization of $398.38 million, a P/E ratio of -5.41 and a beta of -0.69. The stock’s 50-day simple moving average is $6.66 and its 200 day simple moving average is $9.83.
enGene (NASDAQ:ENGN – Get Free Report) last issued its earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.05. As a group, analysts forecast that enGene Holdings Inc. will post -1.56 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Check Out Our Latest Research Report on enGene
Hedge Funds Weigh In On enGene
Several institutional investors and hedge funds have recently modified their holdings of ENGN. Altitude Crest Partners Inc. acquired a new stake in enGene during the 1st quarter worth approximately $2,039,000. SR One Capital Management LP bought a new stake in shares of enGene during the second quarter worth $4,715,000. Janus Henderson Group PLC acquired a new stake in shares of enGene during the first quarter worth $17,095,000. Finally, Logos Global Management LP lifted its position in enGene by 50.0% in the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after acquiring an additional 400,000 shares in the last quarter. 64.16% of the stock is currently owned by institutional investors and hedge funds.
enGene Company Profile
enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
Read More
- Five stocks we like better than enGene
- Bank Stocks – Best Bank Stocks to Invest In
- Survey Reveals: America’s Most Coveted Businesses in 2024
- How to Effectively Use the MarketBeat Ratings Screener
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for enGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for enGene and related companies with MarketBeat.com's FREE daily email newsletter.